These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1279 related articles for article (PubMed ID: 21209123)
21. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203 [TBL] [Abstract][Full Text] [Related]
22. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872 [TBL] [Abstract][Full Text] [Related]
23. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Colombel JF; Rutgeerts P; Reinisch W; Esser D; Wang Y; Lang Y; Marano CW; Strauss R; Oddens BJ; Feagan BG; Hanauer SB; Lichtenstein GR; Present D; Sands BE; Sandborn WJ Gastroenterology; 2011 Oct; 141(4):1194-201. PubMed ID: 21723220 [TBL] [Abstract][Full Text] [Related]
24. Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Wolf D; D'Haens G; Sandborn WJ; Colombel JF; Van Assche G; Robinson AM; Lazar A; Zhou Q; Petersson J; Thakkar RB Aliment Pharmacol Ther; 2014 Sep; 40(5):486-97. PubMed ID: 25041859 [TBL] [Abstract][Full Text] [Related]
25. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Sandborn WJ; Hanauer SB; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh DG; Panaccione R; Wolf D; Kent JD; Bittle B; Li J; Pollack PF Gut; 2007 Sep; 56(9):1232-9. PubMed ID: 17299059 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study). Hibi T; Imai Y; Senoo A; Ohta K; Ukyo Y J Gastroenterol; 2017 Oct; 52(10):1101-1111. PubMed ID: 28324167 [TBL] [Abstract][Full Text] [Related]
27. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Kimball AB; Kerdel F; Adams D; Mrowietz U; Gelfand JM; Gniadecki R; Prens EP; Schlessinger J; Zouboulis CC; van der Zee HH; Rosenfeld M; Mulani P; Gu Y; Paulson S; Okun M; Jemec GB Ann Intern Med; 2012 Dec; 157(12):846-55. PubMed ID: 23247938 [TBL] [Abstract][Full Text] [Related]
28. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy. Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209 [TBL] [Abstract][Full Text] [Related]
30. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Van Assche G; Sandborn WJ; Feagan BG; Salzberg BA; Silvers D; Monroe PS; Pandak WM; Anderson FH; Valentine JF; Wild GE; Geenen DJ; Sprague R; Targan SR; Rutgeerts P; Vexler V; Young D; Shames RS Gut; 2006 Nov; 55(11):1568-74. PubMed ID: 16603634 [TBL] [Abstract][Full Text] [Related]
31. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Danese S; Vermeire S; Zhou W; Pangan AL; Siffledeen J; Greenbloom S; Hébuterne X; D'Haens G; Nakase H; Panés J; Higgins PDR; Juillerat P; Lindsay JO; Loftus EV; Sandborn WJ; Reinisch W; Chen MH; Sanchez Gonzalez Y; Huang B; Xie W; Liu J; Weinreich MA; Panaccione R Lancet; 2022 Jun; 399(10341):2113-2128. PubMed ID: 35644166 [TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. van der Heijde D; Kivitz A; Schiff MH; Sieper J; Dijkmans BA; Braun J; Dougados M; Reveille JD; Wong RL; Kupper H; Davis JC; Arthritis Rheum; 2006 Jul; 54(7):2136-46. PubMed ID: 16802350 [TBL] [Abstract][Full Text] [Related]
33. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Hanauer SB; Sandborn WJ; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh D; Panaccione R; Wolf D; Pollack P Gastroenterology; 2006 Feb; 130(2):323-33; quiz 591. PubMed ID: 16472588 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus. Yamamoto S; Nakase H; Matsuura M; Honzawa Y; Masuda S; Inui K; Chiba T J Gastroenterol Hepatol; 2010 May; 25(5):886-91. PubMed ID: 20546441 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis. Sandborn WJ; Cyrille M; Hansen MB; Feagan BG; Loftus EV; Rogler G; Vermeire S; Cruz ML; Yang J; Boedigheimer MJ; Abuqayyas L; Evangelista CM; Sullivan BA; Reinisch W Gastroenterology; 2019 Mar; 156(4):946-957.e18. PubMed ID: 30472236 [TBL] [Abstract][Full Text] [Related]
36. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Feagan BG; Sandborn WJ; Lazar A; Thakkar RB; Huang B; Reilly N; Chen N; Yang M; Skup M; Mulani P; Chao J Gastroenterology; 2014 Jan; 146(1):110-118.e3. PubMed ID: 24067881 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of Fufangkushen colon-coated capsule in the treatment of ulcerative colitis compared with mesalazine: a double-blinded and randomized study. Gong Y; Zha Q; Li L; Liu Y; Yang B; Liu L; Lu A; Lin Y; Jiang M J Ethnopharmacol; 2012 Jun; 141(2):592-8. PubMed ID: 21911045 [TBL] [Abstract][Full Text] [Related]
38. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Sandborn WJ; Rutgeerts P; Feagan BG; Reinisch W; Olson A; Johanns J; Lu J; Horgan K; Rachmilewitz D; Hanauer SB; Lichtenstein GR; de Villiers WJ; Present D; Sands BE; Colombel JF Gastroenterology; 2009 Oct; 137(4):1250-60; quiz 1520. PubMed ID: 19596014 [TBL] [Abstract][Full Text] [Related]